EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58  – Posting: # 20959
Views: 1,696

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
20,453 posts in 4,295 threads, 1,414 registered users;
online 26 (0 registered, 26 guests [including 23 identified bots]).
Forum time (Europe/Vienna): 22:21 CET

My dear, science is a cruel mistress.    Paul Shenar (as Dr. Laurence)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5